PMID: 9185911Jun 1, 1997Paper

bcl-2 expression in pilomatricoma

The American Journal of Dermatopathology
S Farrier, M Morgan

Abstract

Pilomatricoma is a distinctive tumor characterized by a dual population of proliferating basophilic cells and diagnostic shadow cells, believed to arise from the hair matrix. The normal hair matrix undergoes defined cycles of growth (anagen), regression (catagen), and resting (telogen) that are regulated by programmed cell death (apoptosis). bcl-2 is a proto-oncogene that helps to suppress apoptosis in both benign and malignant tumors. In addition, both apoptosis and bel-2 are critical factors in normal hair follicle development. In order to clarify the role of bcl-1, we used immunohistochemical means to study 10 cases of histologically proven pilomatricoma for bcl-2 expression. The study design included both positive and negative controls. All of the pilomatricomas in our series were strongly decorated by bcl-2 immunostaining. Based on our findings of increased bcl-2 staining, we concluded that the faulty suppression of apoptosis contributes to the pathogenesis of pilomatricoma.

References

Apr 1, 1966·The Journal of Investigative Dermatology·K HashimotoW F Lever
Mar 1, 1994·Developmental Dynamics : an Official Publication of the American Association of Anatomists·R R PolakowskaA R Haake
May 1, 1995·The British Journal of Dermatology·M E VerhaeghH A Neumann
Mar 10, 1995·Science·H Steller
Jul 1, 1994·The Journal of Investigative Dermatology·K S StennM Seiberg
Jul 1, 1994·The British Journal of Dermatology·B R SmollerR A Warnke
Jan 28, 1993·Nature·M D JacobsonM C Raff
Apr 1, 1995·The American Journal of Dermatopathology·S KadduH Kerl
Dec 1, 1959·The Journal of Investigative Dermatology·A M KLIGMAN

❮ Previous
Next ❯

Citations

May 25, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Agoston T AgostonSara O Vargas
May 8, 1999·The British Journal of Dermatology·B CribierE Grosshans
Nov 15, 2000·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·J KimG L Ellis
May 11, 1999·Journal of Cutaneous Pathology·T Nakamura
Jun 24, 2014·International Journal of Pediatric Otorhinolaryngology·Daniel KwonRobin Dyleski
Oct 22, 2008·Survey of Ophthalmology·Jaime LevyJacob Pe'er
Mar 10, 2004·Journal of Cutaneous Pathology·Assia BassarovaSvetlana Christova
May 17, 2006·The Journal of Dermatology·Harun CiralikOzer Arican
Jun 5, 2014·Pediatric Dermatology·Ian C C KingManiram Ragbir
Jun 5, 2015·Orbit·Yu-Yun Huang, Chieh-Chih Tsai
Jul 3, 2018·Pediatric Dermatology·Camile RichetJuliette Mazereeuw-Hautier
Jan 23, 2008·Ophthalmic Plastic and Reconstructive Surgery·José M Abalo-LojoFrancisco Gonzalez
Nov 26, 2003·British Journal of Neurosurgery·J J FitzGeraldM Cartmill
Feb 3, 2021·BMJ Case Reports·Korikkar Mahaling Veena, Jagadish Chandra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis